The remote self-assessment of vital capacity in patients with MND

The remote self-assessment of vital capacity in patients with MND - RESAVICA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49485

Enrollment

Registered

2020-06-12

Start date

2020-08-24

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS Amyotrofic Lateral Sclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. 18 years or older 2. Diagnosed with motor neuron disease (MND): amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA) or primary lateral sclerosis (PLS). 3. Able to perform a respiratory function test with or without caregiver assistance

Exclusion criteria

Exclusion criteria: 1. Tracheostomy Ventilation 2. Severe cognitive impairment

Design outcomes

Primary

Measure	Time frame
The mean difference between the supervised VCs and the self-assessed VCs, and the standard deviation of the difference (validity).	—

Secondary

Measure	Time frame
- Within patient variability of the self-assessed VC during follow-up (reliability). - Feasibility of a 4-weekly home-monitoring protocol. o Adherence: number of completed home assessments divided by total number of home assessments. o Acceptability: Patients* perspectives on the burden, frequency and difficulty of the home assessments.	—

Countries

Netherlands

Outcome results